QUALIblood SA is pleased to announce a strategic partnership with Immuneed AB, a Swedish specialised Service Provider in non-clinical research.
This collaboration marks a significant milestone in both companies’ missions to drive innovation, efficiency, and value for their customers and stakeholders.
Through this partnership, QUALIblood SA and Immuneed AB will leverage their respective strengths to bring new capabilities to the market, combining the specific strengths and technologies of both companies, e.g., specialised expertise in whole-blood assays, human-relevant immunological assessment, inflammatory markers, dynamic coagulation and fibrinolysis activation evaluation or drug-induced hemolysis. Together, the companies aim to address key challenges in the pre-clinical and clinical drug development phases while offering complementary solutions to the customers. By having access to each partner’s services, the customer can combine needed assays in one project and thereby have a streamlined process supported by highly qualified expertise.
“Our partnership with Immuneed AB represents a shared vision for the future of Drug Development,” said Julie Winand, CEO of QUALIblood SA. “By combining our resources and expertise, we will be able to deliver a more comprehensive offering that meets the diverse needs of our clients, from enhanced blood profiling to cutting-edge immune response analysis.”
QUALIblood SA’s expertise in blood investigation, providing bioanalytical support to pharmaceutical companies and research institutions engaged in drug development aligns seamlessly with Immuneed AB´s commitment to supporting drug developers with human-relevant immunological assessments for preclinical-stage molecules, creating a unique opportunity for mutual growth and advancement.
“We are thrilled to partner with QUALIblood SA to deliver more advanced and scalable solutions to our customers,” said Camilla Oldgren CEO of Immuneed AB. This collaboration enables us to expand our offerings in ways that weren’t earlier possible, setting a new standard in Drug Development for innovation, quality, and customer satisfaction.”
The partnership will include customer referrals, combined studies and co-marketing where applicable.
